Aarhus University Seal / Aarhus Universitets segl

Kristian Stengaard-Pedersen

Methotrexatbehandling af rheumatoid artritis i Danmark

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

In the recommended early, aggressive and continuous treatment strategy of rheumatoid arthritis (RA), methotrexate (MTX) is the anchor drug, and although generally well tolerated approximately 50% of the RA patients discontinue MTX treatment within five years. In a large Danish cohort study among newly diagnosed patients with RA only 21% had started MTX treatment within 90 days after referral to hospital and the median time-to-treatment initiation was 120 days. Furthermore, MTX compliance is considered generally high among Danish RA patients and the patients have strong beliefs about MTX necessity.
Original languageDanish
JournalUgeskrift for Laeger
Volume173
Issue36
Pages (from-to)2187-2189
Number of pages3
ISSN0041-5782
Publication statusPublished - 5 Sep 2011

See relations at Aarhus University Citationformats

ID: 40446582